Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Lyell Immunopharma's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.11.
Lyell Immunopharma's long-term debt to total assets ratio
declined
from Mar. 2025 (0.11) to Mar. 2026 (0.11).
It may suggest that Lyell Immunopharma is progressively becoming less dependent on debt to grow their business.
LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.
Lyell Immunopharma LT-Debt-to-Total-Asset Related Terms
Lyell Immunopharma LT-Debt-to-Total-Asset Historical Data
* Premium members only.
The historical data trend for Lyell Immunopharma's LT-Debt-to-Total-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lyell Immunopharma (LYEL) has a LT-Debt-to-Total-Asset of 0.11 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Lyell Immunopharma and its competitors.
Is Lyell Immunopharma's LT-Debt-to-Total-Asset too high?
Lyell Immunopharma's current LT-Debt-to-Total-Asset is 0.11. Overall, Lyell Immunopharma has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lyell Immunopharma's LT-Debt-to-Total-Asset compare to ALXO and ARMP?
Lyell Immunopharma's LT-Debt-to-Total-Asset of 0.11 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Lyell Immunopharma and its competitors. Lyell Immunopharma's current LT-Debt-to-Total-Asset is 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyell Immunopharma stock overvalued right now?
Based on GuruFocus' analysis, Lyell Immunopharma (LYEL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.26, compared to a current price of $13.19 — trading 150.8% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.11. Lyell Immunopharma's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Lyell Immunopharma (LYEL), the current LT-Debt-to-Total-Asset is 0.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lyell Immunopharma (LYEL) Overvalued in 2026?
Based on GuruFocus' analysis, Lyell Immunopharma stock appears to be overvalued.
The current stock price of $13.19 is trading 150.8% above its estimated GF Value™ of $5.26.
GuruFocus considers Lyell Immunopharma to be Significantly Overvalued.
Key valuation signals for LYEL:
LT-Debt-to-Total-Asset: 0.11
GF Value™: $5.26 vs. price of $13.19 (150.8% above fair value)
No single metric tells the full story. See the LYEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
55GF Score
Get the complete analysis for LYEL
LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LYEL has been successfully added to your 
